Stockhead reports Race gets ethics nod for Phase I trial in solid tumour patients

Race Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour.

The full report can be accessed via this link.